Curiosity in Colombia’s medical marijuana market is booming, however a Marijuana Enterprise Every day evaluation exhibits that – out of over 100 licensed cannabis firms working within the nation – few have completed registering their first cultivars, a prerequisite to rising crops for industrial functions.
To this point, no firm is promoting or exporting medical cannabis commercially.
That highlights the challenges – and future milestones – nonetheless going through companies working in Colombia’s medical marijuana business.
As of Could 2019, solely 4 firms had totally registered cultivars with the Colombian Agricultural Institute (ICA):
- Intelligent Leaves
- FCM International
- Santa Marta Golden Hemp, which is 60% owned by the Canadian biotech firm Avicanna.
A 12 months in the past, most Colombian cannabis firms have been centered on acquiring licenses and securing funding.
At this time, many boast immense licensed areas, theoretical manufacturing capacities, refined advertising plans and low anticipated prices of manufacturing. However obligatory regulatory points nonetheless stay the important thing hurdle prone to separate the leaders from the remainder of the pack – probably within the close to future.
Till the tip of 2018, licensed firms may reap the benefits of an industrywide amnesty that allowed them to register seeds with the ICA with out having to justify their origin.
Not having to show the origin of seeds supplied a bonus over newcomers. People who didn’t begin the registration earlier than Dec. 31 might want to supply their beginning supplies from domestically registered seeds or import them.
Andres Lopez, former head of Colombia’s Nationwide Narcotics Fund, defined that “the prolonged course of to acquire ICA registry for every cultivar requires experimentation from seed to reap in line with a strict methodology outlined by ICA.”
“On the finish of the method, flower yield, cannabinoid content material and different technical info of the particular cultivar is audited by the ICA,” he stated. “Upon profitable outcomes, an ICA workforce points an approval, known as ‘acta,‘ mandatory for the ICA to complete the method with a decision, the ultimate doc that certifies the registration of the cultivar.”
With out totally registered genetics with the ICA, rising cannabis for industrial functions is just not doable.
The next firms completed the agronomic analysis assessments with the ICA, in line with info MJBizDaily had entry to. The chart consists of info at the moment out there on the ICA web site and more moderen documentation supplied by a number of firms:
|Psychoactive cannabis cultivars||Nonpsychoactive cannabis cultivars||Complete|
|Santa Marta Golden Hemp||3||1||4|
*Pharmacielo introduced it “obtained approval” from the ICA for 10 cultivars in February 2019 and for 10 extra varieties in March 2019. MJBizDaily had entry to the “actas” approving the agronomic analysis, however not the ultimate resolutions, which the corporate acknowledged haven’t but been issued by the ICA.
MJBizDaily is just not conscious of another firm that totally registered genetics as of Could 2019, however that can not be dominated out.
MJBizDaily reached out to a number of Colombian firms through e-mail – together with Khiron (TSXV: KHRN), Spectrum (Cover Development subsidiary), Colcanna (Aphria subsidiary), MED Colombia (Aurora subsidiary), Blueberries Medical (CSE: BBM), Pideka and Foliumed – to find out if that they had completed registering genetics with the ICA or after they anticipate to finish the primary ones.
Blueberries, Foliumed and Khiron replied:
- Camilo Villalba, chief working officer of Blueberries, advised MJBizDaily that the corporate is within the “ultimate part of the agronomic analysis assessments” and expects “to acquire the primary industrial varieties with excessive contents of CBD in the course of the Q3 of 2019.”
- Diego Navarro, CEO of Foliumed, additionally expects to finalize the registration of the primary genetics in “Q3 of 2019.
- A Khiron spokesperson declined to remark.
No industrial quotas granted up to now
Along with the licensing system, the nation regulates manufacturing and distribution of “psychoactive” merchandise via a quota system. The system permits manufacturing of “psychoactive cannabis” – outlined as THC larger than or equal to 1% – solely after a particular quota is granted.
No firm at the moment has obtained a industrial quota. Allowances have been made just for analysis and improvement.
Lopez summarized the trail to promote merchandise containing psychoactive cannabis as follows:
- License holders should end their genetics characterization course of with the ICA.
- They need to full an R&D course of for oils or extracts to be exported or used domestically, offering technical and high quality specs of potential merchandise.
“Earlier than granting any commercialization quota, the federal government grants an R&D quota for firms to indicate they’ll produce a steady and clearly outlined product,” Lopez stated.
To this point, the one export from Colombia has been for testing functions.
Just one firm is at the moment legally promoting merchandise with CBD content material inside Colombia’s home market. Khiron began gross sales after receiving approval a 12 months in the past to promote CBD-infused cosmetics.
Blueberries not too long ago stated it obtained approval to promote comparable merchandise. However whereas Khiron merchandise are already out there within the Colombian market, Blueberries plans to begin promoting in the course of the second half of this 12 months.
As a result of these merchandise will not be bought as medical cannabis, no medical claims may be made.
Contemplating Khiron had no registered cultivars as of Could 2019, it seems the corporate is importing CBD to fabricate cosmetics and isn’t utilizing its personal crops grown in Colombia. The corporate declined to confirm when requested by MJBizDaily.
Blueberries stated the CBD it used to provoke the manufacturing of beauty merchandise was imported to Colombia from america.
Alfredo Pascual may be reached at [email protected]